COVID‑19 Cicada Variant Spreads
The BA.3.2 variant of COVID-19, nicknamed Cicada, features significant genetic changes that may impact vaccine effectiveness for patients with chronic lung disease.
The BA.3.2 variant of COVID-19, nicknamed Cicada, features significant genetic changes that may impact vaccine effectiveness for patients with chronic lung disease.
Backed by approximately $500 million in investment from Big Tech, the Intercept initiative will back broad-spectrum preventatives and air-cleaning technologies to reduce the global health burden of respiratory infections.
Researchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
Underlying chronic conditions and hospital transfers are major indicators of severe disease in pediatric patients with respiratory tract infections.
Real-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
Researchers discovered manikomycin, a soil-derived peptide that attacks bacteria in a unique way to bypass existing antibiotic resistance.